Los Angeles Capital Management LLC Cuts Position in Catalyst Pharmaceuticals, Inc. $CPRX

Los Angeles Capital Management LLC trimmed its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 15.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 136,599 shares of the biopharmaceutical company’s stock after selling 25,800 shares during the quarter. Los Angeles Capital Management LLC owned 0.11% of Catalyst Pharmaceuticals worth $3,188,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Royal Bank of Canada raised its holdings in shares of Catalyst Pharmaceuticals by 39.1% during the 1st quarter. Royal Bank of Canada now owns 213,469 shares of the biopharmaceutical company’s stock valued at $5,177,000 after buying an additional 60,040 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Catalyst Pharmaceuticals by 5.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,052 shares of the biopharmaceutical company’s stock valued at $1,749,000 after buying an additional 3,800 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 11.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after buying an additional 333,100 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Catalyst Pharmaceuticals by 99.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 526,297 shares of the biopharmaceutical company’s stock valued at $12,763,000 after buying an additional 262,392 shares during the period. Finally, Intech Investment Management LLC raised its holdings in shares of Catalyst Pharmaceuticals by 6.5% during the 1st quarter. Intech Investment Management LLC now owns 70,087 shares of the biopharmaceutical company’s stock valued at $1,700,000 after buying an additional 4,261 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Up 0.2%

Shares of NASDAQ CPRX opened at $31.34 on Wednesday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.05 and a fifty-two week high of $32.56. The business has a 50 day moving average price of $28.74 and a two-hundred day moving average price of $25.47. The firm has a market cap of $3.84 billion, a PE ratio of 18.01, a price-to-earnings-growth ratio of 0.95 and a beta of 0.74.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Oppenheimer downgraded Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Zacks Research downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Weiss Ratings upgraded Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 3rd. Robert W. Baird downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Finally, HC Wainwright downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the company from $35.00 to $31.50 in a report on Thursday, May 28th. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).